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SrcOnce thought to be present only in liver, muscle and adipose tissue, the GH receptor is now known to be
ubiquitously distributed, in accord with the many pleiotropic actions of GH. These include the regulation of
metabolism, postnatal growth, cognition, immune, cardiac and renal systems and gut function. GH exerts these
actions primarily through alterations in gene expression, initiated by activation of its membrane receptor and
the resultant activation of the associated JAK2 (Janus kinase 2) and Src family kinases. Receptor activation
involves hormone initiatedmovements within a receptor homodimer, rather than simple receptor dimerization.
We have shown that binding of the hormone realigns the orientation of the two receptors both by relative
rotation and by closer apposition just above the cell membrane. This is a consequence of the asymmetric
placement of the binding sites on the hormone. Binding results in a conversion of parallel receptor trans-
membrane domains into a rotated crossover orientation, which produces separation of the lower part of the
transmembrane helices. Because the JAK2 is bound to the Box1 motif proximal to the inner membrane, receptor
activation results in separation of the two associated JAK2s, and in particular the removal of the inhibitory
pseudokinase domain from the kinase domain of the other JAK2 (and vice versa). This brings the two kinase
domains into position for trans-activation and initiates tyrosine phosphorylation of the receptor cytoplasmic
domain and other substrates such as STAT5, the key transcription factor mediating most genomic actions of GH.
There are a limited number of genomic actions initiated by the Src kinase family member which also associates
with the upper cytoplasmic domain of the receptor, including important immune regulatory actions to dampen
exuberant innate immune activation of cells involved in transplant rejection. These ﬁndings offer insights for
developing speciﬁc receptor antagonists which may be valuable in cancer therapy.
Crown Copyright © 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
While the postnatal growth enhancing actions of growth hormone
(GH) are best known, GH also has a wide range of actions in the regula-
tion of metabolism, (particularly in the liver and adipose tissue), as well
as actions on the immune, reproductive and cardiovascular systems,
and the brain [3]. For example, hepatic steatosis and gluconeogenesis
are GH regulated, as are many cytochrome P450 enzymes involved in
detoxiﬁcation and drugmetabolism. These have beenbest characterised
in rodents, but the limited human evidence available supports human
applicability. GH status is known to inﬂuence cognitive ability, and we
have shown that GH is required for neural stem cell proliferation and
formation of new neurons in response to exercise, while GH/IGF1 also
inﬂuences synaptic connection formation [12]. In relation to immune
function, GH inﬂuences many cellular immune elements, either directly
or via IGF1 generation. For example, it is able to increase helper CD4 T-
cell number in AIDS patients, and we have shown that GH induces ex-
pression of the mouse homolog of HLA-G, a key immune-tolerancer Ltd. This is an open access article uprotein able to dampen the innate immune response [1]. Given the
ubiquity of expression of the GH receptor (GHR) as demonstrated
both by immunohistochemical means and by transcript analysis, it
was evident that GH would have actions in every tissue of the body,
and this has subsequently been veriﬁed bymany studies [3]. It is impor-
tant to understand that GH acts through mediators for many of its ac-
tions. Thus, as well as induction of IGF1, GH is able to upregulate the
EGF, oestrogen and androgen receptors, and the angiotensin II receptor,
and we showed that GH upregulates the expression of BMP2/4 and the
BMP 1A receptor [3,10,18].
The actions of GH are a result of activation of its receptor, and loss of
function of this receptor has, as one would surmise from the above,
many consequences. Because GH is amodulator, such a loss is not lethal,
but results in a sub optimal health with short stature, decreased bone
mineral density and concentration, decreased muscle strength, thin
skin and hair, delayed puberty and increased adiposity, and hepatic
steatosis, along with impaired cognitive ability in several ﬁelds [3].
Interestingly, these patients are highly resistant to cancer, and in the
Ecuadorian cohort of 100, no cancer deaths were observed [8]. Con-
versely, prolonged activation of the receptor as a result of a variant
sequence in its cytoplasmic domain which impairs the binding of thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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risk from lung cancer [7].
2. Structure of the GH receptor
Given the importance of its physiologic actions, what dowe know of
theGH receptor itself? This receptorwas theﬁrst class 1 cytokine recep-
tor to be cloned, and has been an exemplar for the 30 receptors in this
class, which include the receptors for erythropoietin, prolactin, leptin,
thrombopoietin, LIF, CTNF, oncostatin-M, carditropin-1 and most of
the interleukins, together with many of the haematopoietic colony-
stimulating factors. These form homodimers or heterodimers with ac-
cessory proteins such as gp 130, common beta and common gamma
chains (Fig. 1 and ref. [16]). They are all singlemembrane pass receptors
possessing a characteristic domain structure in their extracellular do-
mains referred to as a cytokine receptor homology domain, which con-
sists of two ﬁbronectin III likemodules, eachwith a seven stranded beta
sandwich structure which is the focus of ligand binding. A conserved
WSxWS motif is present in the lower FNIII module (YGeFS for the
GHR), necessary for expression and stability of these receptors. Many
of these receptors release their extracellular domain into the circulation,
and in the case of the GHR this produces the circulating GH binding pro-
tein, which regulates GH availability [2]. The key common element for
this class of receptor is the conserved proline rich Box 1 motif, which
is necessary for binding of their cognate tyrosine (Janus) kinase, the
main target of the receptor activation process. This is located close to
the cell membrane, and N-terminal to the less conserved Box 2 se-
quence consisting of aromatic and acidic residues. The Janus kinases
phosphorylate not only certain tyrosine residues in the receptor cyto-
plasmic domain, but also other protein substrates directly. In the case
of the GHR, key tyrosine residues in the cytoplasmic domain serve as
docking sites for SH2-domain containing proteins, notably STAT5a and
STAT5b, whichmediate a considerable part of GH action at the genome.
Docking of these transcription factors facilitates their phosphorylation
by the JAK2 at tyrosine 699, resulting in STAT5 dimer formation and
translocation to the nucleus where the dimer regulates target geneFig. 1.Domain structures of class 1 cytokine receptors showing disulphide bonded domain 1 (ye
Common subunits shared by heteromeric receptors also shown.expression [11]. Recently we elucidated the structure of the cytoplasmic
domain of both theGHR and the prolactin receptor, and found them to be
intrinsically disordered, with some transient alpha-helical structure [9].
Intrinsically disordered structure was also observed for the shared
gp130 subunit of other class 1 receptors and would confer maximal
ﬂexibility on the cytoplasmic domain, allowing it to bind multiple pro-
teins as well as access to the membrane proximal JAK2 for phosphory-
lation of its target tyrosines.
3. Activation of the GH receptor
While it is generally believed that class 1 cytokine receptors are ac-
tivated by ligand-dependent dimerization/oligomerization, we and
others have shown that the GH, EPO and prolactin receptors exist as di-
mers at the cell surface before binding of the cognate ligand (reviewed
in [16]). Using receptor truncationswith FRET and BRET reporters at the
N- or C-terminus, we showed that themajor element responsible for di-
merization of the unliganded receptor was the helical transmembrane
domains. This has necessitated a reappraisal of the receptor activation
mechanism, focusing on ligand-induced conformational change or sub-
unit realignment (see [17] for an account of the history). Initially we
sought ligand dependent changes in the extracellular domain by com-
paring the Genentech crystal structure of the GH(receptor)2 structure
with our unliganded receptor crystal structure [5]. However, this
revealed no substantial difference in disposition of the peptide chain
between receptor 1 in the ternary complex and the unliganded recep-
tor. Hence the remaining option: realignment of the receptors as a result
of binding the hormone which possesses two binding sites, placed
asymmetrically. Our previous mutational studies had shown that the
receptor–receptor interaction surface in the extracellular domain (site
3, involving the lower Fibronectin III domain) must lock together for
signalling to occur [6]. Evidently the asymmetric placement of the re-
ceptor binding sites on the hormone aligns these site 3 surfaces, so
they can lock together. Evidence for such a realignment was published
by Poger and Mark [13], wherein in silico removal of the hormone
from the GH(receptor)2 complex in GROMOS resulted in relativellow) and domain 2 (red), with Box 1 and 2 sequences wand the conservedWSxWSmotif.
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putative unliganded state of the dimer.
We explored the role of receptor realignment by replacing the extra-
cellular domain of the receptorwith a jun zipper, to clamp the receptors
in speciﬁc alignments [4]. We used two parallel sets of constructs, one
with the complete cytoplasmic domain to observe signalling to STAT5,
and a second with a FRET reporter place below the Box 1 motif. In this
waywe could correlatemovements of the Box 1motif with receptor ac-
tivation. We found that the closer the zippers were to the cell surface,
the stronger was the STAT5 activation signal. There was also an effect
of rotation, with a maximum activation at a particular rotational posi-
tion conferred by insertion of alanine residues at themembrane surface.
We then introduced a charge reversal into the highly conserved EED se-
quence just above the membrane, and found that combining EED with
KKR markedly increased the STAT5 activation (this was also effective
with the full length native receptor). They key point here is that with
each of these strategies there was an INVERSE relationship between ac-
tivation and the FRET signal ie the more active constructs resulted in
INCREASED separation of the Box 1 sequences.We tested this surprising
conclusion in the full length receptor with hGH itself, then with the
charge reversal approach, then using the GH antagonist hGHG120R,
and ﬁnally the Laron dwarf mutation D170H in Site 3, which does not
inﬂuence hormone binding, but does block signalling. In each case we
ran a parallel set of constructs with the C-terminal FRET reporters to
monitor movement of Box 1. In each case the inverse relation was ob-
served between activity and FRET signal, with the G120R blocking the
ability of hGH to decrease the FRET signal, while the D170H receptor
mutation did not show the decrease in FRET signal seen on addition of
hGH.
To understand the movements of the transmembrane domains
(TMDs) necessary to separate the Box 1 sequences upon receptor acti-
vation, we took two approaches [4]. In the ﬁrst, we converted every
TMD residue, as well as nearby juxtamembrane residues, individually
to cysteine. We then crosslinked these using a short crosslinker and
rannon-reducing SDS gels to separatemonomer anddimer for each res-
idue substitution, thus providing proximity estimates for individual res-
idues. This provided us with the relationship between the two TM
helices in the dimer in the unliganded (basal) state. We had hoped to
see a difference on addition of ligand (hormone), but the helix move-
ment on activation was insufﬁcient to show in the crosslinking, except
at the cell surface. These studies did however, provide us with theFig. 2. Transmembrane helix rearrangement upon activation of the receptor, derived frommol
the active form by closer approach of the N-termini, leading to a rotation and left hand crossovbasal state for the molecular dynamics modelling we the then under-
took. For these studies, we placed the TMDs in a lipid bilayer (DPPC)
and moved them slowly together, observing their orientation and
resulting free energies. The helices interacted strongly, driven by entro-
pic and lipid interactions, initially in a parallel arrangement as seenwith
the crosslinking studies for the unliganded receptor. Further approach,
as would be a consequence of locking of Site 3 through hormone bind-
ing, converted the parallel form to a left handed crossover form, with
separation of the C-termini of the helices, as observed in the FRET stud-
ies (Fig. 2). This movement to a crossover arrangement required a rota-
tion of helices resulting in close contact of two conserved glycine
residues in the centre of the TMD, with removal of two phenylalanine
residues from the interaction surface of the parallel dimer. It was grati-
fying that when we docked the active helix crossover form with the
crystal structure of the 1:2 complex, the ﬁt was facile, and resulted in
close proximity of Cys 259 in the upper juxtamembrane segment, in
accordance with the formation of a spontaneous disulphide bond on
hormone binding.
4. Activation of JAK2
Having established the helixmovements involved in receptor activa-
tion, the next task was to understand how a separation of Box 1 motifs
could activate the associated JAK2s, which work in tandem. A key point
here is that these tyrosine kinases possess, unusually, a pseudokinase
inhibitory domain. This must be removed from the catalytic kinase do-
main for signalling to occur. We hypothesised that if the pseudokinase
domain of one JAK2 was inhibiting the kinase domain of the other
JAK2, then a separation of Box 1motifs could slide the pseudokinase do-
main away from the other kinase domain, and bring the two kinase do-
mains into proximity for trans-activation to occur ([4], see Fig. 3).
Evidence for this model was ﬁrst obtained by placing FRET reporters
at the positions of the kinase domain and at the pseudokinase domain.
We used the charge reversal mutant to avoid the problem of cryptic re-
ceptors inmembrane vesicleswithout access to the hormone. Itwas ob-
served that when the receptor became activated the pseudokinase
domains became more separated (lower FRET signal), while the kinase
domain FRET reporters gave a stronger signal, as predicted. Second, we
swapped the kinase and pseudokinase domains, reasoning that if the
domain swap was co-transfected with the native JAK2, this would
place the kinase domains together, conferring constitutive activity.ecular dynamics simulations in a lipid bilayer. The basal state (parallel helices) converts to
er of the helices with separation of the C-termini.
Fig. 3. Schematic of activation process for JAK2, driven by separation of the receptor C-termini. This removes the inhibitory pseudokinase of one JAK2 from the kinase domain of the other
JAK2 (and vice versa), relieving inhibition and bringing the kinase domains together for trans-activation.
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association of pseudokinase–kinase pairs by Alpha screen and single
molecule ﬂuorescence coincidence measurement, while the kinase do-
mains alone did not associate. Finally, we docked the crystal structures
of the kinase and pseudokinase domains of JAK2 and found a minimum
energy conﬁguration that allowed for orientations satisfying our Box1
separation hypothesis. This conﬁguration could also explain the oncoge-
nicity of several known JAK2mutations, including the V617Fmutant ev-
ident in polycythemia vera.
Together, these ﬁndings are illustrated in a ﬂash animation showing
the activation process: http://web-services.imb.uq.edu.au/waters/hgh.
html.
5. In vivo analysis of signalling by the GHR and Src family kinases
Some years ago, when the nature of the signal for postnatal growth
was unknown,we sought to identify it with targeted knockinmutations
in the cytoplasmic domain of the receptor, using mice. From a series of
truncations we correlated postnatal growth with ability to activate
STAT5, and identiﬁed GH-regulated transcripts associated with signal-
ling from the different parts of the receptor cytoplasmic domain [14].
These mice have also allowed us to identify the elements involved in
the ability of GH to promote browning of white adipose tissue, as part
of its ability to decrease adiposity. They have also been useful in identi-
fying elements responsible for the insulin-antagonistic actions of GH.
In addition to the receptor truncations referred to above, wemade a
knockinmutantwith Box 1 disabled by alanine substitution of the 4 pro-
lines [15]. The dwarfmutant was unable to activate JAK2 or STAT5 in re-
sponse to GH administration, but was able to activate Src signalling to
ERK. This was in agreement with in vitro studies we had performed
showing that a Src family kinase (SFK) associates with the GHR, and
can signal independently of JAK2 with a different orientation of the
TMD, in this case leading to activation of ERK and Jun [15]. The physio-
logical consequences of this were unclear until we performed microar-
ray analysis of the transcripts in the livers of these mice, and compared
the proﬁle with that of the GHRKO [1].We identiﬁed transcripts speciﬁc
to the Src-ERK-Jun pathway which included the mouse homolog of a
potent immunotolerance protein known as HLA-G. Serum levels of
this protein correlatewith success of renal, cardiac, lung and liver trans-
plants in humans, and it is used to protect the foetus from attack by the
maternal immune system. We were able to show that this protein isrequired for liver regeneration in the partial hepatectomy model with
C567Bl/6 mice, and that this gene is induced by the Src-ERK-Jun path-
way in response to GH. Its function is to dampen the innate immune
system which is triggered by the sterile inﬂammatory response pro-
duced by the surgical insult of partial hepatectomy. Replacement of
this gene both by adenoviral delivery and by direct infusion of the pro-
tein prevented these mice from dying within 48 h of the operation and
suppressed markers of immune attack.
6. Conclusion
TheGH receptor uses two tyrosine kinases for its signalling, and they
are activated by different conformational changes within the constitu-
tive dimer. We have elucidated the activation mechanism for JAK2,
and are currently deﬁning themechanism for the SFK component of sig-
nalling. It is anticipated this information will be of use for drug design
purposes, particularly for the creation of a GH antagonist which may
be useful in cancer therapy.
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